Showing 81-90 of 8172 results for "".
New Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tOnline Reputation Management Update
https://practicaldermatology.com/topics/practice-management/online-reputation-management-update/18658/Protecting your online reputation is crucial to your digital marketing success. If you think it's all about spotting and hiding bad reviews, you're wrong. Learn how to build and protect a stellar online reputation for your dermatology practice and how it will actually boost SEO. The Ekwa Marketing tAubio Launches, Updates from Prescriber's Choice, BioPharmX
https://practicaldermatology.com/topics/practice-management/dermwiretv-aubio-launches-updates-from-prescriber-s-choice-biopharmx/18584/In this edition of DermWireTV, Aubio launches OTC treatment for cold sores with backing from Paul Mitchell partner. Prescriber's Choice facilitates in-office prescription dispensing. BioPharmX enrolls phase 2b trial for topical minocycline and Merz acquires ONLight Sciences, maker of PFD patch for tDermWireTV: The Year in Review - 2023!
https://practicaldermatology.com/topics/psoriasis/dermwiretv-the-year-in-review-2023/20229/Practical Dermatology® Co-Chief Medical Editor, Joel Schlessinger, MD, shares his thoughts on some of the best products and approvals of 2023 as well as the potential of new JAK inhibitors to treat alopecia areata, vitiligo, psoriasis, and atopic dermatitis. Our new contributor, Andrew Mastro, PA, tDermWireTV: 2020 in Review
https://practicaldermatology.com/topics/psoriasis/dermwiretv-2020-in-review/19882/Crisaborole ointment became the first and only steroid-free, topical prescription medication for mild to moderate AD in patients as young as three months of age. Ustekinumab is approved for pediatric patients with moderate to severe plaque psoriasis. FDA approved ixekizumab injection, 80mg/mL for tWhen to Consider Therapeutic Switching in Plaque Psoriasis: Best Practices for Nurse Practitioners, Physician Assistants, and Physicians
https://practicaldermatology.com/topics/psoriasis/when-to-consider-therapeutic-switching-in-plaque-psoriasis-best-practices-for-nurse-practitioners-physician-assistants-and-physicians/21054/What to know about patient experiences and the proper approaches to modifying treatment regimens.The Hidradenitis Suppurativa Therapeutic Pipeline
https://practicaldermatology.com/topics/rare-disease/the-hidradenitis-suppurativa-therapeutic-pipeline/54824/Though treatment options are currently limited, the pipeline for HS therapeutics is active with numerous medications in development.Rediscovering Topical Antifungal Therapy for Onychomycosis
https://practicaldermatology.com/topics/hair-nails/rediscovering-topical-antifungal-therapy-for-onychomycosis/22974/A number of potential topical therapies for onychomycosis have failed clinical investigation. Do we at last have a viable alternative to oral treatment options?Topical Steroid Withdrawal in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/topical-steroid-withdrawal-in-atopic-dermatitis/23079/Exploring the important role and proper use of topical corticosteroids in the management of eczema.A User's Guide to the Field of Biologic Therapies
https://practicaldermatology.com/topics/psoriasis/PD0709_01-php/22796/All the facts you need to know about available biologic therapies, assembled in one place.